Forma, Boehringer Sign Oncology Pact | Chemical & Engineering News
Volume 90 Issue 2 | p. 21 | Concentrates
Issue Date: January 9, 2012

Forma, Boehringer Sign Oncology Pact

Department: Business
Keywords: oncology, small molecules, drug discovery

Forma Therapeutics and Boehringer Ingelheim have formed an R&D collaboration aimed at discovering small molecules that act against oncology-relevant protein-protein interactions. Forma will receive $65 million in up-front payments and research funding to screen for and optimize compounds over the next four years. It could get up to $750 million in milestone payments as well. Forma is based on science developed at the Broad Institute. It also has partnerships with Genentech, Eisai, and Novartis.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment